VAXIGRIP® is a sterile suspension of influenza virus for intramuscular or deep subcutaneous injection. It is a purified, inactivated, split virion vaccine.
VAXIGRIP® contains the following strains of influenza virus:
A/Brisbane/59/2007IVR-148 (A/Brisbane/59/2007 [H1N1] - like),
A/Uruguay/716/2007 NYMC X-175C (A/Brisbane/10/2007 [H3N2] - like), and
B/Florida/4/2006 (B/Florida/4/2006 - like)
Each 0.5 mL pre-filled syringe contains 15 mcg haemagglutinin of each of the 3 strains in a buffered saline solution. A buffered saline solution contains the following excipients - sodium chloride, potassium chloride, sodium phosphate - dibasic dihydrate, potassium phosphate - monobasic and water for injection.
The vaccine is prepared from virus grown in the allantoic cavity of embryonated eggs, concentrated, purified by zonal centrifugation in a sucrose gradient, split by octoxinol 9 (Triton X-100), inactivated by formaldehyde and then diluted in phosphate buffered saline solution to the required concentration. No adjuvant or preservative is added. The vaccine may contain traces of formaldehyde (≤ 30 mcg), octoxinol 9 (≤ 150 mcg) and neomycin (< 20 picogram). VAXIGRIP® does not contain more than 0.05 mcg ovalbumin per dose.
The type and amount of viral antigens contained in VAXIGRIP® conform to the annual requirements of the Australian Influenza Vaccine Committee (AIVC) and the World Health Organization (WHO) recommendations for the season. VAXIGRIP® conforms in safety and sterility to the requirements of the British Pharmacopoeia.